Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Deferred Revenue (2016 - 2022)

Myriad Genetics (MYGN) has disclosed Current Deferred Revenue for 12 consecutive years, with $200000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Current Deferred Revenue fell 98.26% to $200000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $200000.0, a 98.26% decrease, with the full-year FY2021 number at $5.2 million, down 84.1% from a year prior.
  • Current Deferred Revenue was $200000.0 for Q3 2022 at Myriad Genetics, down from $300000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $32.8 million in Q2 2020 to a low of $200000.0 in Q3 2022.
  • A 5-year average of $10.2 million and a median of $2.6 million in 2018 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 1438.1% in 2020, then crashed 98.67% in 2022.
  • Myriad Genetics' Current Deferred Revenue stood at $2.4 million in 2018, then skyrocketed by 50.0% to $3.6 million in 2019, then skyrocketed by 808.33% to $32.7 million in 2020, then crashed by 84.1% to $5.2 million in 2021, then tumbled by 96.15% to $200000.0 in 2022.
  • Per Business Quant, the three most recent readings for MYGN's Current Deferred Revenue are $200000.0 (Q3 2022), $300000.0 (Q2 2022), and $700000.0 (Q1 2022).